MEDIA

NEWS ARCHIVES

As CEO of Interface Biologics, Tom Reeves doesn’t dwell on what might have been. For example, a few years ago, as COO of OccuLogix, he came within the blink of an eye of a billion-dollar breakthrough to treat dry age-related macular degeneration.

As CEO of Interface Biologics, Tom Reeves doesn’t dwell on what might have been. For example, a few years ago, as COO of OccuLogix, he came within the blink of an eye of a billion-dollar breakthrough to treat dry age-related macular degeneration.

That particular opportunity is no more, but Mr. Reeves likes his chances with Interface, a closely held biomedical polymer technology company in Toronto. For one thing, Interface is not a one-product company. It has multiple platforms that can be applied to develop multiple devices. And the technology is easily differentiated from the competition. In this exclusive interview with BioTuesday.ca, Mr. Reeves shares his views about the compelling prospects ahead for Interface.